TG Therapeutics公布2025年第四季度及全年财报 上调Briumvi收入预期

美股速递
Feb 26

TG Therapeutics今日披露了2025年第四季度及全年度财务业绩报告。值得注意的是,公司同时宣布上调其核心产品Briumvi的全年收入指引,展现出对业务增长势头的强劲信心。此次调整反映了该药物在市场推广和患者接纳度方面的积极进展,为投资者提供了更明确的价值锚点。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10